Evelo Biosciences, Inc. (EVLO)
OTCMKTS · Delayed Price · Currency is USD
0.0005
0.00 (0.00%)
Jul 31, 2025, 1:16 PM EDT

Evelo Biosciences Company Description

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects.

It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis.

The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology.

Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Evelo Biosciences, Inc.
Evelo Biosciences logo
CountryUnited States
Founded2014
IndustryBiotechnology
SectorHealthcare
Employees66

Contact Details

Address:
620 Memorial Drive
Cambridge, Delaware 02139
United States
Phone617 577 0300

Stock Details

Ticker SymbolEVLO
ExchangeOTCMKTS
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberUS2997341035
SIC Code2836

Key Executives

NamePosition
Craig R. Jalbert CIRAPresident, Secretary, Principal Executive, Financial and Accounting Officer and Director
Dr. Chun Zhang Ph.D.Chief Technical Operations and Quality Officer
Leslie Wardwell-Scott Ph.D.Vice President and Head of Corporate Development and Strategic Integration
Dr. Andrea Itano Ph.D.Head of Research
Dr. Duncan McHale M.D., MBBS, Ph.D.Chief Medical Officer
Douglas MaslinSenior Director and Immunology Clinical Lead